Item 2.02 - Results of Operations and Financial Condition: The filing reports financial results and operational performance for Becton Dickinson & Co as of August 6, 2026 Item 9.01 - Financial Statements and Exhibits: The filing includes financial statements and exhibits related to the reported results Company Information: Becton Dickinson & Co is a surgical and medical instruments & apparatus…

Our analysis rates this filing BULLISH. This filing presents an exceptionally positive financial picture with no material concerns. Becton Dickinson delivered Q3 results that exceeded expectations across multiple dimensions: revenue growth, profitability, and cash generation. The 33.3% increase in…

Concern level: LOW (1.2/10).

Notable risk changes: Strong Q3 FY2026 results with revenue growth of 5.4% as reported (4.4% FXN) and adjusted diluted EPS of $3.23 from continuing operations; Significant cash generation improvement: year-to-date cash from continuing operations increased 33.3% to $2.1 billion and free cash flow increased 44.6% to $1.7 billion; Company raises full-year guidance with expectations for revenue growth toward high end of…

The model predicts BDX will underperform the S&P 500 by about 0.1% over 30 days (model confidence 85%). This is model analysis for research, not investment advice.